Rapport Therapeutics Q3 net loss $17.5M; DPNP IND on clinical hold; cash $320.7M

Rapport Therapeutics, Inc.

2024-Q3 EPS reported -$3.66

Net loss $17.5M vs $8.7M prior year; R&D expense $15.5M (up from $7.6M) driven by clinical development.
Cash, equivalents, and short-term investments $320.7M; expected to fund operations through end of 2026.
RAP-219 Phase 2a focal epilepsy trial on track; topline data expected mid-2025. MAD-2 and PET results Q1 2025.
FDA placed IND for diabetic peripheral neuropathic pain (DPNP) on clinical hold; focal epilepsy trial unaffected.
Appointed four new board members (Rob Perez, Raymond Sanchez, Paul Silva, Wendy Young); Jeff Tong resigned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.